Co-Existence of Carbapenemase-Encoding Genes in *Acinetobacter baumannii* from Cancer Patients

Reham Wasfi · Fatma Rasslan · Safaa S. Hassan · Hossam M. Ashour · Ola A. Abd El-Rahman

Received: September 20, 2020 / Accepted: October 24, 2020 / Published online: November 12, 2020 © The Author(s) 2020

**ABSTRACT**

**Introduction:** *Acinetobacter baumannii* is an opportunistic pathogen, which can acquire new resistance genes. Infections by carbapenem-resistant *A. baumannii* (CRAB) in cancer patients cause high mortality.

**Methods:** CRAB isolates from cancer patients were screened for carbapenemase-encoding genes that belong to Ambler classes (A), (B), and (D), followed by genotypic characterization by enterobacterial-repetitive-Intergenic-consensus–polymerase chain reaction (ERIC–PCR) and multilocus-sequence-typing (MLST).

**Results:** A total of 94.1% of CRAB isolates co-harbored more than one carbapenemase-encoding gene. The genes *bla*\(^{NDM}\), *bla*\(^{OXA-23}\)-like, and *bla*\(^{KPC}\) showed the highest prevalence, with rates of 23 (67.7%), 19 (55.9%), and 17 (50%), respectively. ERIC-PCR revealed 19 patterns (grouped into 9 clusters). MLST analysis identified different sequence types (STs) (ST-268, ST-195, ST-1114, and ST-1632) that belong to the highly resistant easily spreadable International clone II (IC II). Genotype diversity indicated the dissemination of carbapenem-hydrolyzing, β-lactamase-encoding genes among genetically unrelated isolates. We observed a high prevalence of metallo-β-lactamase (MBL)-encoding genes (including the highly-resistant *bla*\(^{NDM}\) gene that is capable of horizontal gene transfer) and of isolates harboring multiple carbapenemase-encoding genes from different classes.

**Conclusion:** The findings are alarming and call for measures to prevent and control the spread of MBL-encoding genes among bacteria causing infections in cancer patients and other immunocompromised patient populations.

**Keywords:** Cancer; Carbapenem-resistant *Acinetobacter baumannii* (CRAB); Metallo-β-lactamase (MBL); Multilocus sequence typing (MLST)
**Key Summary Points**

The majority (94.1%) of carbapenem-resistant *A. baumannii* (CRAB) isolates from cancer patients harbored more than one carbapenemase-encoding genes.

We observed a high prevalence of metallo-β-lactamase-encoding genes including blaNDM, blaOXA-23-like, and blaKPC.

MLST analysis identified different STs that belong to the highly resistant easily spreadable International clone II.

Measures should be implemented to control the spread of this clone.

---

**DIGITAL FEATURES**

This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.13134965.

**INTRODUCTION**

Cancer patients are high-risk, immunocompromised, and may experience long hospital stays. Thus, they are more prone to infections with opportunistic bacteria such as *Acinetobacter baumannii* [1]. *A. baumannii* is a Gram-negative, aerobic, non-motile coccobacillus. Moreover, it is an opportunistic pathogen that can cause severe, life-threatening healthcare-associated infections such as bacteremia, pneumonia, meningitis, and endocarditis [2]. The fairly recent emergence and increased prevalence of multidrug-resistant (MDR) *A. baumannii* is worrisome. *A. baumannii* is now listed by the World Health Organization as one of the critical pathogens, which highlights the need for the development of new antimicrobials [5]. This can be attributed to the increased resistance to multiple antibiotics, including last resort antibiotics, such as carbapenems, which are reserved for cases when all alternatives have been exhausted (typically used with MDR bacteria in hospitalized patients) [6]. The high resistance patterns of *A. baumannii* are due to the upregulation of intrinsic antimicrobial resistance genes in addition to their genomic plasticity, allowing the acquisition of new resistance genes through mobile genetic elements such as plasmids and transposons [7]. Many mechanisms can decrease susceptibility of *A. baumannii* to carbapenems, including the production of carbapenemase enzyme [10], loss of outer membrane proteins [11], overexpression of multidrug efflux pumps [12], and alterations in penicillin-binding proteins [2].

Among the previous mechanisms, the production of carbapenemase enzyme is considered to be the main mechanism of resistance to carbapenems [10]. Serine carbapenemases and metallo-β-lactamases are two carbapenemase groups that have been defined according to their active sites. Serine carbapenemases include class (A) penicillinases and class (D) oxacillinases, whereas class (B) carbapenemases belong to metallo-β-lactamases (MBL) that are inhibited by EDTA. Class (A) carbapenemases include the IMI/NMC, SME, KPC, and GES enzymes, whereby KPC and GES enzymes are plasmid-encoded and thus highly spreadable [13]. Class (B) MBL include IMP, VIM, GIM, SIM, and NDM enzymes, whose genes are mainly found in transferable plasmids. The NDM-encoding gene was first detected in a *Klebsiella pneumoniae* isolate [14]. NDM-1 has spread worldwide and is one of the most common carbapenemases in Enterobacteriaceae and *A. baumannii* [15]. Class (D) β-lactamases are also known as oxacillinases, for ‘oxacillin-hydrolyzing’, or OXA β-lactamases. Genes encoding OXA β-lactamases are present in plasmids and chromosomes. Worldwide, the most common OXA-encoding gene groups in *A. baumannii* are the OXA-23, OXA-24/40, and OXA-58 groups, whereas OXA-143 has only been detected from *A. baumannii* isolates in Brazil [16]. OXA-48 can typically be detected in *K. pneumoniae* [13]. The oxacillinase are relatively lower in activity than other types of carbapenemases, but overexpression of these genes has been observed in the presence of...
insertion sequences (IS) upstream of these genes which can provide additional promoters [17]. There are three “worldwide” clonal lineages (International clones: ICs I, II, and III) for A. baumannii [18]. The international clone II shows worldwide spread in many hospitals which can be attributed to the ability of this lineage to incorporate new genes and their adaptation to hospital environment [2]. The rapid spread of multidrug-resistant A. baumannii clinical isolates among cancer patients in the last two decades is worrisome because infection by this bacteria is associated with a high rate of mortality among this vulnerable group [8].

The aim of the current study was to investigate the dissemination of carbapenemase-encoding genes among carbapenem-resistant A. baumannii (CRAB) isolates from cancer patients followed by the genotypic analysis of these isolates. This will help to tailor the antimicrobial protocols in healthcare settings and to improve infection control policies.

METHODS

Bacterial Isolates

A total of 520 isolates were recovered from blood samples in cases of blood infection of cancer patients at the National Cancer Institute (NCI), Giza, Egypt, from July 2017 to January 2018. Ethical approvals were obtained from the Ethics committees of the NCI and the Faculty of Pharmacy, October University for Modern Sciences and Arts. Consents from patients were obtained before the inception of the study. Samples were streaked on CHROMagar Acinetobacter supplemented with CR102 (CHROMagar, France) for isolation of multidrug-resistant Acinetobacter sp., then isolated colonies were identified using the VITEK2 automated system (BioMerieux, Marcy-l’Étoile, France). Identification was confirmed by polymerase chain reaction (PCR) amplification of the intrinsic blaOXA-51-like [19], in addition to using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF/MS) (Microflex LT; Bruker Daltonics) [20]. All isolates were preserved in glycerol broth at −20 °C.

Antimicrobial Susceptibility Testing

Antimicrobial susceptibility patterns were determined by the VITEK2 system and the results were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [21]. The classes of antibiotics used in this test included β-lactams, aminoglycosides, quinolones, folate pathway inhibitors, glycolcycline, and polymyxin. Minimum inhibitory concentrations (MICs) of meropenem and colistin, for all CRAB isolates, were determined by the agar dilution, and micro-broth dilution methods, respectively, according to the CLSI [21] guidelines.

Detection of the Carbapenemase-Encoding Genes

Pure colonies of carbapenem-resistant isolates were used for DNA extraction using the Thermo Scientific™ GeneJet™ genomic DNA purification kit (Thermo Scientific, MA, USA), according to the manufacturer’s recommendations and kept at −20 °C. PCR was performed to screen for the presence of carbapenemase-encoding genes belonging to Ambler classes (A), (B), and (D), using the primers and annealing temperatures described in Table 1. Genes were amplified by initial denaturation at 94 °C for 5 min, followed by 35 cycles consisting of 3 phases: DNA denaturation at 94 °C for 0.5 min, annealing according to Table 1 for 0.5 min, and elongation at 72 °C for time (1 Kb/1 min); finally, elongation at 72 °C for 10 min. A combination of forward ISAba1 primer and reverse primers of class (D) encoding genes were used to detect the presence of the ISAba1 insertion element upstream carbapenemase-encoding genes [17]. Negative control was included in all PCR assays.

Molecular Typing of CRAB Isolates by Enterobacterial Repetitive Intergenic Consensus–PCR (ERIC–PCR) and Multilocus Sequence Typing (MLST)

Clonal relatedness of collected isolates was examined via enterobacterial repetitive
| Ambler class | Genes to be amplified | F/R | Primer sequences (5’–3’) | Annealing temp. (°C) | Expected product size (bp) | References |
|-------------|-----------------------|-----|--------------------------|----------------------|--------------------------|------------|
| Class A     | blaKPC                | F   | GCC GTG CAA TAC AGT GAT AAC | 54                   | 276                      | This study |
|             |                       | R   | GCC GGT CGT GTT TCC CTT    |                      |                          |            |
|             | blaGES                | F   | GAT ACA ACT ACG CCT ATT GCT | 52                   | 99                       | This study |
|             |                       | R   | CAG CCA CCT CTC AAT GGT G  |                      |                          |            |
| Class B     | blaNDM                | F   | GGT TGGCGATCTGGTTTTC       | 53                   | 621                      | [61]       |
|             |                       | R   | CGGAATGGCTCATCAAGGATC      |                      |                          |            |
|             | blaVIM like           | F   | GATGGTGTGGTGGTGCAT         | 54                   | 390                      | [61]       |
|             |                       | R   | CGAATGGCGAGGACCAG          |                      |                          |            |
|             | blaIMP like           | F   | TTT GTG GAG CGT GGC TAT AAA | 54                   | 117                      | This study |
|             |                       | R   | TAA TTC AGA TGC ATA CGT GGG |                      |                          |            |
|             | blaSIM                | F   | TGG CTA AGA CTA TGA AGC    | 46                   | 272                      | This study |
|             |                       | R   | AAA CGA GAA GAC CTT GCC    |                      |                          |            |
|             | blaGIM                | F   | TCG ACA CAC CTT GGT CTA GAA | 54                   | 477                      | [37]       |
|             |                       | R   | AAC TTC CAA CTT TGC CAT GC |                      |                          |            |
|             | blaSIM                | F   | TAC AAG GGA TTC GGC ATG G   | 54                   | 571                      | [37]       |
|             |                       | R   | TAA TGG CCT GTT CCC ATG TG |                      |                          |            |
| Class D     | blaOXA 51             | F   | TAA TGC TTT GAT CGG CCT TG | 54                   | 370                      | [61]       |
|             |                       | R   | TGG ATT GCA CTT CAT CTT GG |                      |                          |            |
|             | blaOXA 23             | F   | GAT CGG ATT GGA GAA CGAGA  | 54                   | 501                      | [61]       |
|             |                       | R   | ATT TCT GAC CGC ATT TCC AT |                      |                          |            |
|             | blaOXA-24/40          | F   | GGT TAG TTT GCC CCC TTA AA | 54                   | 246                      | [61]       |
|             |                       | R   | AGT TGA CGG AAA AGG GGA TT |                      |                          |            |
|             | blaOXA 58             | F   | AAG TAT TGG GGC TGG TGC TG | 54                   | 599                      | [61]       |
|             |                       | R   | CCC CTC TGC GCT CTA CAT AC |                      |                          |            |
| Insertion element | ISAba1 | F   | CAC GAA TGC AGA AGT TG | 46                   | 549                      | [61]       |
|             |                       | R   | CGA CGA ATA CTA TGA CAC    |                      |                          |            |
| ERIC primers | ERIC2                |     | AAGTAAGTGA CACTGGG TGAGCG | 49                   | –                        | [22]       |
intergenic consensus (ERIC)–PCR, which was carried out as described previously by Versalovic et al. [22] using ERIC2 primer (Table 1). Electrophoretic patterns were analyzed by using the BioNumerics software v.7.6 (Applied Maths, Sint-Martens-Latem, Belgium). The BioNumerics analysis was performed using the Dice coefficient and the unweighted pair group method of averages (UPGMA) with a 1% tolerance limit and 1% optimization. Isolates that clustered with ≥ 80% similarity were grouped into one ERIC type. Representative isolates from ERIC clusters of 100% similarity were subjected to typing by multilocus sequence typing (MLST), which was performed according to the Oxford scheme protocol using primers listed in the A. baumannii MLST database website (https://pubmlst.org/abaumannii/). Amplification of the seven conserved housekeeping genes (gltA, gryB, gdhB, recA, cpn60, rpoD, and gpi) was performed according to the protocol proposed by Bartual et al. [23]. Sanger sequencing was carried out using the ABI 3730xl DNA Analyzer at the Macrogen sequencing facility (Macrogen/C210, South Korea). The allelic numbers and sequence types (STs) were defined by means of the A. baumannii MLST database. Clusters of related STs (defined as clonal complexes; CCs) were analyzed using the Global Optimal eBURST (goeBURST) by the Phyloviz 2.0 software (https://www.phyloviz.net/goeburst). Analysis of clonal complex was carried out at the level of single locus variant (SLV) and double loci variant (DVL).

RESULTS

Antibiotic Susceptibility of Collected Isolates

Forty-eight A. baumannii non-duplicate isolates were recovered from 520 blood samples representing 15.1% of total isolates. The A. baumannii isolates were recovered from 43 hospitalized patients and 5 outpatients. The identification of the A. baumannii isolates up to the species level was confirmed by the detection of the intrinsic blaOXA-51-like gene and the MALDI-TOF/MS. The antibiotic resistance of the isolates was determined by VITEK2, and six resistance patterns were detected. A total of 34 out of the 48 isolates (70.8%) were found to be resistant to meropenem and ertapenem and were, hence, designated as CRAB. The 34 CRAB isolates were recovered from cancer patients (5 outpatients and 29 inpatients). Resistance to tigecycline and colistin (last-resort antibiotics) was detected in 7/34 (20.5%) and 1/34 (2.9%) of CRAB isolates, respectively (Table 2). The MICs of meropenem against tested isolates ranged from 8 to ≥ 128 μg/ml (Table 3).

Detection of Carbapenemase-Encoding Genes

Co-existence of more than one carbapenemase-encoding gene was detected in 28/34 (82.3%) of CRAB isolates. The carbapenemase-encoding resistance genes blaNDM, blaOXA-23-like, and blaKPC showed the highest prevalence of 67.7%, 55.9%, and 50% of CRAB isolates, respectively. The Ambler class (B) MBL genes were detected in 31/34 (91%) of isolates. Among the MBL genes detected, in addition to blaNDM, were blaGIM, blaSPM, blaSIM, and blaIMP in 38.2%, 29.4%, 8.8%, and 5.8% of CRAB isolates, respectively, while blaVIM was not detected in any of the collected isolates. The class (D) oxacillinase coding genes blaOXA24/40 and blaOXA58 were detected in 26.4% and 2.9% of CRAB isolates, respectively. Class (A) GES gene was detected in 9/34 (26.4%) of isolates. The insertion element was detected upstream of blaOXA 23-like in two isolates (ID.27 and 41), blaOXA24/40-like in two isolates (ID 38 and 41), while it was upstream of blaOXA 51-like in one isolate (ID.7) (Table 3).

Molecular Typing of CRAB Isolates

ERIC-PCR typing revealed that the 34 CRAB isolates were grouped into 9 clusters and classified into 19 ERIC types according to 80% cut off. Eric type “3” was the most prevailing and represented by 7 isolates (Fig. 1). The predominant cluster was G which contains 7 isolates, followed by D(5), H (5), C (4), B (3), E (3), F (3), A (2), and I (2). Isolates with 100% ERIC typing
similarities were found to be collected within 0–3 months. MLST was carried out for six isolates as representative for each of the groups in Table 3, and belonging to ERIC clones showing 100% similarity. The most prevalent MLST type was ST 286 (3 isolates), followed by ST 195, ST 1114, and ST 1632, represented by one isolate each (Table 4). Isolates typed as MLST ST 286 were found to be isolated from the same hospital floor but from different wards. ST relatedness to CCs was analyzed by the eBURST algorithm. eBURST analysis showed that all the identified STs belong to a founder ST208. ST 286 and ST 195 were SLV of gpi locus from founder,

Table 2 Antimicrobial sensitivity patterns of carbapenem resistant A. baumannii (CRAB) isolates

| Isolate ID | Antimicrobial resistance profile | Beta lactam | Aminoglycoside | Quinolone | Glycylcyline | Polymyxin | Folate pathway inhibitors |
|------------|----------------------------------|-------------|----------------|------------|--------------|------------|--------------------------|
| 1-2-4-7-14-22-24-25-28-29-30-31-32-33-35-36-37-38-39-40-41-43 | MER-ERT- CXT-CAZ- CTX-CPM- AMC-SAM | GEN-TOB-AMK | CIP-LEV | – | – | SXT |
| 6-15 | MER-ERT- CXT-CAZ- CTX-CPM- AMC-SAM | GEN-TOB-AMK | CIP-LEV | – | – | – |
| 9 | MER<sup>a</sup>-ERT<sup>a</sup>- CXT-CAZ- CTX-CPM- AMC-SAM | GEN-TOB-AMK | CIP-LEV | TGC | COL | SXT |
| 12 | MER-ERT- CXT-CAZ- CTX-CPM- AMC-SAM | GEN-TOB | CIP-LEV | – | – | SXT |
| 21-44 | MER-ERT- CXT-CAZ- CTX-CPM- AMC-SAM | CIP-LEV | – | – | SXT |
| 23-26-27-45-46-47 | MER-ERT- CXT-CAZ- CTX-CPM- AMC-SAM | GEN-TOB-AMK | CIP-LEV | TGC | – | SXT |

*MER* Meropenem, *ERT* Ertapenem, *CXT* Cefoxitin, *CAZ* Ceftazidime, *CTX* Cefotaxime, *CPM* Cefepem, *AMC* Amoxicillin/Clavulanic acid, *SAM* Ampicillin/sulbactam, *Gen* Gentamicin, *TOB* Tobramycin, *AMK* Amikacin, *CIP* Ciprofloxacin, *LEV* Levofoxacin, *TGC* Tigecycline, *COL* Colistin, *SXT* Sulfamethoxazole/trimethorpime

(—) Indicates sensitivity to antimicrobial agent

<sup>a</sup> Indicates moderate resistance

**Table 2 Antimicrobial sensitivity patterns of carbapenem resistant A. baumannii (CRAB) isolates**
Table 3 Minimum inhibitory concentration (MIC), carbapenemase-encoding genes, ERIC type of 34 carbapenem-resistant A. baumannii isolates

| ID | Inpatient/ outpatient | MIC μg/ml | Carbapenem-hydrolyzing enzymes | ERIC type |
|----|-----------------------|-----------|-------------------------------|-----------|
|    |                       | Inpatient | Class A | Class B | Class D | IS.Aba1 |
|    |                       | Outpatient |          |          |          |         |
|    | Mer | Class A | Class B | Class D | IS.Aba1 |
|    | Class D | IS.Aba1 |         |          |          |         |

**One class of carbapenemase-encoding genes**

2 Inpatient 32 – – OXA23, OXA51 + E2a
4 Inpatient 32 – – OXA23, OXA51 + E2b

**Two classes of carbapenemase-encoding genes**

14 Inpatient 32 KPC – OXA23, OXA51 - E2c
15 Inpatient 32 – NDM, GIM OXA23, OXA51 - E2d
24 Inpatient 32 – NDM OXA23, OXA51 - E3b
25 Inpatient 128 – NDM OXA51 + E9
30 Inpatient > 128 – NDM OXA51 + E11
33 Inpatient > 128 – NDM, SPM, GIM OXA23, OXA51 + E14

**Three classes of carbapenemase-encoding genes**

6 Inpatient > 128 KPC GIM OXA51 + E3a
7 Outpatient 32 KPC NDM, GIM OXA23, OXA51 + E4
9 Inpatient 8 KPC NDM, SPM, GIM OXA51, OXA23 + E5

**Mer** Meropenem, (+) detected gene, (−) no detected genes

*a IS.Aba1 upstream Ambler Class D carbapenemase-encoding gene
while ST 1114 and ST 1632 were SLV from ST437 and DLV from ST 208 founder in gyrP and gpi loci (Fig. 2). All identified STs were found to belong to CC92 (International clone II).

**DISCUSSION**

Cancer patients are at higher risk of acquiring *A. baumannii* infections due to several factors, including their immunocompromised state and lengthy hospital stays [10]. Infections by CRAB isolates pose a great threat for cancer patients because they are associated with a high mortality rate. The ability of *A. baumannii* to resist the reserved antibacterial agents including carbapenems is alarming, hence raising the importance of studying its prevalence and mechanism of resistance to control its spread.

Carbapenem insensitivity was detected in 70.8% (34/48) of collected isolates, which is similar to other studies carried in Egypt by Sultan and Seliem [24]. Others have shown a higher prevalence for CRAB reaching 90% [10, 25, 26], which suggests that Egypt is the topmost country in the region in CRAB prevalence [27]. CRAB treatment typically relies on other last-resort antibiotics such as colistin and tigecycline and sometimes antibiotic combinations [28]. This becomes more challenging when isolates also exhibit resistance to last-resort antibiotics. About 21% of CRAB isolates were resistant to tigecycline; a similar prevalence of tigecycline resistance was detected by Kamel et al. [29].

Co-occurrence of a variety of intrinsic and acquired carbapenemase-encoding genes has been detected with increased prevalence for acquired carbapenemase-encoding genes known to be carried on mobile elements. Isolates co-harboring more than one acquired carbapenemase-encoding genes account for 32/34 (94.1%) of CRAB isolates. Clones carrying multiple carbapenemase-encoding genes have been detected in many studies carried out in the Middle East region [30–32], and in China [33].

Ambler class (A) *bla*KPC and *bla*GES genes were detected in 50% and 26.5% of CRAB isolates, respectively. The increased spread of the *bla*KPC and *bla*GES in *A. baumannii* clinical isolates in Egypt reached a prevalence of 56% and 48%, respectively, in Benmahmod et al.’s [26] study. The high spreading capacity of the *bla*KPC and *bla*GES genes could be attributed to their linkage to mobile elements such as *Tn*4401 located on conjugative plasmids [34] and integrons [35], respectively, facilitating their horizontal transfer. The *bla*GES-encoding gene is usually associated with a low level of carbapenem resistance (MIC 4–16 μg/ml) [9], while in the current study carbapenem MIC in isolates harboring *bla*GES-encoding gene was detected.

---

**Table 4** Multilocus sequence types (MLSTs), allele profiles, and clonal complex of six carbapenem-resistant *A. baumannii* isolates

| ID | Allele profile | ST | Clonal complex (CC) |
|----|----------------|----|---------------------|
|    | gltA gyrB gdhB recA cpn60 gpi rpoD |    |                     |
| 4  | 1 3 3 2 2 163 3 | 286 | 92                  |
| 6  | 1 12 3 2 2 195 3 | 1632| 92                  |
| 23 | 1 3 3 2 2 96 3  | 195 | 92                  |
| 35 | 1 3 3 2 2 163 3 | 286 | 92                  |
| 41 | 1 3 3 2 2 163 3 | 286 | 92                  |
| 45 | 1 12 3 2 2 79 3  | 1114| 92                  |
encoding gene ranged from 16 to ≥ 128 μg/ml due to the co-existence of other carbapenemase-encoding genes. Infection with A. baumannii carrying $bla_{KPC}$ is usually associated with a high level of morbidity and mortality [36].

MBL-encoding genes were detected in 91% of CRAB isolates which is worrisome, because
these genes are usually correlated with high MIC [37], and they are characterized by rapid spread and high transferability between bacteria [38]. MBL-producing bacteria are a potentially great threat to modern intensive care treatment protocols [39]; hence, rapid detection and good infection control are required to reduce their impact. MICs in MBL-carrying isolates ranged from 16 to \( \geq 128 \mu g/ml \) except for one isolate (ID 9) which might indicate mutation in the MBL gene of this isolate. Class (B) carbapenemase-encoding genes including \( \text{bla}_{\text{NDM}}, \text{bla}_{\text{GIM}}, \text{bla}_{\text{SIM}}, \text{bla}_{\text{SPM}}, \text{bla}_{\text{IMP}}, \) and \( \text{bla}_{\text{IMP}} \) were detected in 67.7%, 38.2%, 29.4%, 8.8%, and 5.8% of CRAB isolates, respectively.

High prevalence of \( \text{bla}_{\text{NDM}} \) gene (67.7% of CRAB isolates) was observed in our study compared to previous studies carried out in Egyptian hospitals which showed \( \text{bla}_{\text{NDM}} \) prevalence of 8% [40] and 39.3% [25] among CRAB isolates. The \( \text{bla}_{\text{NDM}} \) encoding genes were first described in \( A. \text{baumannii} \) isolated from Egyptian patients [41] and then a noteworthy spread of \( \text{bla}_{\text{NDM}} \) positive \( A. \text{baumannii} \) was detected in the Middle East [42]. There are several proved mechanisms for horizontal transfer of \( \text{bla}_{\text{NDM}} \)-encoding gene. Jamal et al. [43] found that the transfer of MBL carbapenemase genes was associated with Tn125-type transposon and can be harbored by a plasmid or rarely integrated into the chromosome. The plasmid-harboring \( \text{bla}_{\text{NDM}} \) gene in \( A. \text{baumannii} \) was found to exhibit high transformation frequency via outer membrane vesicles [44]. Another mechanism for horizontal spread of \( \text{bla}_{\text{NDM}} \) gene among \( A. \text{baumannii} \) is by phage transduction [45]. A noteworthy observation in this study was the co-existence of MBL-encoding genes in some isolates which has been detected in many studies carried out in countries which suffer from uncontrolled antibiotic misuse [9, 31, 32, 46]. Lee and his colleagues found that strains harboring multiple plasmids that encode different carbapenemases showed increased fitness and virulence even in the absence of antibiotics which could increase the spread of this strain and emphasize the need for a strategy to combat this strain [47].

The increased prevalence of co-existing MBL could be attributed to the association of these genes by class 1 (sometimes class 3) integrons, which, in turn, are embedded in transposons, resulting in a highly transmissible genetic apparatus [48]. Integrons facilitate movement of resistance genes between integrons in plasmids, and the plasmids allow transfer of genetic material to different bacteria.

Oxacillinase-encoding genes can be intrinsic (\( \text{bla}_{\text{OXA-51-like}} \)) or acquired (\( \text{bla}_{\text{OXA-23-like}}, \text{bla}_{\text{OXA-24/40-like}}, \text{bla}_{\text{OXA-58-like}} \)). Two isolates (ID 2, 4) were found to harbor solely the \( \text{bla}_{\text{OXA-like}} \) genes and they were found to be inhibited by relatively lower concentrations of meropenem compared to isolates harboring other types of carbapenemase genes. The oxacillinase enzymes only weakly hydrolyze carbapenems, but it was found that the insertion of a sequence such as IS\( Aba1 \) upstream of the \( \text{bla}_{\text{OXA-like}} \) genes may enhance the gene expression by conferring strong promoter activity. This insertion sequence could also explain the high capacity of the \( \text{bla}_{\text{OXA-like}} \) genes for horizontal transfer and increased clonal diversity [49]. Numerous studies in Egypt and the Mediterranean regions have classified \( \text{bla}_{\text{OXA-23}} \) like gene as the most common carbapenemase-encoding gene [9, 40, 50–52]. In our study, the \( \text{bla}_{\text{OXA-23}} \) like gene was detected in 64% of CRAB isolates, which is similar to the previously mentioned results. Our findings showed that clusters carrying IS\( Aba1 \) are widely distributed in our hospital, reaching 21/34 (61%), which might explain the high spread of acquired resistance genes among isolates. The \( \text{bla}_{\text{OXA-58}} \) gene prevalence reported here (2.9%) is lower than previously published rates from Tunisia (4%), Egypt (9.1%) [53], and Algeria (14.7%) [54].

The diversity of ERIC patterns obtained in our study suggests dissemination of carbapenem-hydrolyzing \( \beta \)-lactamase-encoding genes among genetically unrelated isolates of \( A. \text{baumannii} \). This may be attributed to horizontal gene transfer of plasmids carrying resistance determinants. Isolates with ERIC typing similarity of 100% showed similarity in antibiotic resistance pattern, except for isolates (ID 6, 24), (ID 2, 5), and (ID 14, 23).

MLST was carried out for six isolates as representative for ERIC clones showing 100% similarity, and which was isolated from the same
The high prevalence of carbapenemase-encoding genes (including MBL-encoding genes such as \(\text{bla}_{\text{NDM}}\)) and their co-existence in CRAB isolates is worrisome. This is due to the potential for high spreadability and the possibility of further dissemination of the highly antibiotic-resistant genes to other bacteria. This can make treatment of these cases very challenging, especially in the immunocompromised cancer patient population. Overall, the findings are alarming and call for strict control measures to prevent the spread of these genes among bacteria causing infections in immunocompromised patient populations.

ACKNOWLEDGEMENTS

Funding. No funding or sponsorship was received for this study or publication of this article. The Rapid Service Fee was funded by the authors.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures. Reham Wasfi, Fatma Rasslan, Safaa S. Hassan, Hossam M. Ashour and Ola A. Abd El-Rahman have nothing to disclose.

Compliance with Ethics Guidelines. Ethical approvals were obtained from the Ethics committees of the National Cancer Institute (NCI) and the Faculty of Pharmacy, October University for Modern Sciences and Arts. Consents from patients were obtained before the inception of the study.

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
REFERENCES

1. Turkoglu M, Mirza E, Tunçcan ÖG, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011;26:460–7.

2. Zarrilli R, Pournaras S, Giannouli M, Tsakris A. Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents. 2013;41:11–9.

3. Fan L, Wang Z, Wang Q, et al. Increasing rates of Acinetobacter baumannii infection and resistance in an oncology department. J Cancer Res Ther. 2018;14:68–71.

4. Montefour K, Frieden J, Hurst S, et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Critical Care Nurse. 2008;28:15–25.

5. WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accessed 17 February 2020.

6. World Health O. The 2019 WHO AWaRe classification of antibiotics for evaluation and monitoring of use. Geneva: World Health Organization; 2019.

7. Mohd Rani F, Rahman NI A, Ismail S, et al. Acinetobacter spp. infections in malaysia: a review of antimicrobial resistance. Trends Mech Epidemiol. 2017. https://doi.org/10.3389/fmicb.2017.02479.

8. Gedik H, Simşek F, Kantürk A, et al. Bloodstream infections in patients with hematological malignancies: which is more fatal—cancer or resistant pathogens? Ther Clin Risk Manag. 2014;10:743–52.

9. Abouelfetouh A, Torky AS, Aboulmagd E. Phenotypic and genotypic characterization of carbapenem-resistant Acinetobacter baumannii isolates from Egypt. Antimicrob Resist Infect Control. 2019;8:188.

10. Al-Hassan L, Zafer MM, El-Mahallawy H. Multiple sequence types responsible for healthcare-associated Acinetobacter baumannii dissemination in a single centre in Egypt. BMC Infect Dis. 2019;19:829.

11. Siroy A, Cosette P, Seyer D, et al. Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. J Proteome Res. 2006;5:3385–98.

12. Siroy A, Molle V, Lemaître-Guillier C, et al. Channel formation by CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii. Antimicrob Agents Chemother. 2005;49:4876–83.

13. Queenan AM, Bush K. Carbapenemases: the Versatile β-Lactamases. 2007; 20:440-58

14. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-β-lactamase gene, <em>blaNDM-1</em>, and a novel erythromycin esterase gene carried on a unique genetic structure in <em>Klebsiella pneumoniae</em> sequence type 14 from India. 2009; 53: 5046–54.

15. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785–96.

16. Zander E, Bonnin RA, Seifert H, Higgins PG. Characterization of blaOXA-143 variants in Acinetobacter baumannii and Acinetobacter pittii. Antimicrob Agents Chemother. 2014;58:2704–8.

17. Turton JF, Ward ME, Woodford N, et al. The role of IS5aI in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett. 2006;258:72–7.

18. Adams-Haduch JM, Onuoha EO, Bogdanovich T, et al. Molecular epidemiology of carbapenem-non-susceptible Acinetobacter baumannii in the United States. J Clin Microbiol. 2011;49:3849–54.
19. Le Minh V, Thi Khanh Nhu N, Vinh Phat V, et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam. J Med Microbiol 2015; 64:1162–9.

20. Marı́-Almirall M, Cosgaya C, Higgins PG, et al. MALDI-TOF/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species. Clin Microbiol Infect 2017; 23:210–e1–e9.

21. CLSI. Performance standard for antimicrobial susceptibility testing; clinical and laboratory standard institute guidelines. 2018.

22. Versalovic J, Koeth T, Lupski R. Distribution of repetitive DNA sequences in eubacteria and application to finerpriting of bacterial enomes. Nucleic Acids Res. 1991;19:6823–31.

23. Bartual SG, Seifert H, Hippler C, Luzon MA, Wisplinghoff H, Rodriguez-Valera F. Development of a multilocus sequence typing scheme for characterization of clinical isolates of Acinetobacter baumannii. J Clin Microbiol. 2005;43:4382–90.

24. Sultan AM, Seliem WA. Identifying risk factors for healthcare-associated infections caused by carbapenem-resistant acinetobacter baumannii in a neonatal intensive care unit. Sultan Qaboos Univ Med J. 2018;18:e75–80.

25. Alkasaby NM, Zaki ME. Molecular study of acinetobacter baumannii isolates for metallo-b-lactamas and extended-spectrum-b-lactamases genes in intensive care unit, Mansoura University Hospital, Egypt. Int J Microbiol 2017; 2017:3925868

26. Al-Sultan AA, Evans BA, Aboulmagd E, et al. Dissemination of multiple carbapenem-resistant clones of Acinetobacter baumannii in the Eastern District of Saudi Arabia. Fronti Microbiol 2015; 6: 634

27. Gomaa FAM, Helal ZH, Khan MI. High Prevalence of bla(NDM-1), bla(VIM), qacE, and qacEAl Genes and Their Association with Decreased Susceptibility to antibiotics and common hospital biocides in clinical isolates of Acinetobacter baumannii. Microorganisms 2017; 5

28. Girija SA, Jayaseelan VP, Arumugam P. Prevalence of VIM- and GIM-producing Acinetobacter baumannii from patients with severe urinary tract infection. Acta Microbiol Immunol Hung. 2018;65: 539–50.

29. Zhou S, Chen X, Meng X, et al. “Roar” of blaNDM-1 and “silence” of blaOXA-58 co-exist in Acinetobacter pittii. Sci Rep. 2015;5:8976.

30. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne J-P. Epidemiology of carbapenem-producing enterobacteriaceae and acinetobacter baumannii in Mediterranean countries. Biomed Res Int. 2014; 2014:305784

31. Bogaerts P, Naas T, El Garch F, et al. GES extended-spectrum beta-lactamases in Acinetobacter baumannii isolates in Belgium. Antimicrob Agents Chemother. 2010;54:4872–8.

32. Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria. South Med J. 2011;104:40–5.

33. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicr Chemother. 2007;59:321–2.

34. Palzkill T. Metallo-b-lactamase structure and function. Ann N Y Acad Sci. 2013;1277:91–104.

35. Khan AU, Maryam L, Zarrilli R. Structure, Genetics and Worldwide Spread of New Delhi Metallo-b-lactamase (NDM): a threat to public health. BMC Microbiol 2017; 17:101

36. El-Bannah AMS, Nawar NN, Hassan RMM, Salem STB. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Egypt: clonal spread of blaOXA-23. Microb Drug Resist. 2018;24:269–77.

37. Kamel NA, El-Tayeb WN, El-Ansary MR, Mansour MT, Aboshanab KM. Phenotypic screening and molecular characterization of carbapenemase-producing gram-negative bacilli recovered from febrile neutropenic pediatric cancer patients in Egypt. PLoS ONE. 2018;13:e0202119.
42. Ghazawi A, Sonnevend A, Bonnin RA, et al. NDM-2 carbapenemase-producing Acinetobacter baumanii in the United Arab Emirates. Clin Microbiol Infect. 2012;18:E34–6.

43. Jamal S, Al Atrouni A, Rafei R, Dabboussi F, Hamze M, Osman M. Molecular mechanisms of antimicrobial resistance in Acinetobacter baumannii, with a special focus on its epidemiology in Lebanon. J Global Antimicro Resist. 2018;15:154–63.

44. Chatterjee S, Mondal A, Mitra S, Basu S. Acinetobacter baumannii transfers the blaNDM-1 gene via outer membrane vesicles. J Antimicrob Chemother. 2017;72:2201–7.

45. Krahn T, Wibberg D, Maus I, et al. Intraspecies Transfer of the Chromosomal Acinetobacter baumannii blaNDM-1 Carbapenemase Gene. Antimicrob Agents Chemother. 2016;60:3032–40.

46. Santimaleeworagun W, Samret W, Preechachawong P, Kerdsin A, Jitwasinkul T. Emergence of co-carbapenemase genes, BLA(OXA23), BLA(VIM) and BLA(NDM) in carbapenem-resistant acinetobacter baumannii clinical isolates. Southeast Asian J Trop Med Pub Health. 2016;47:1001–7.

47. Lee H, Shin J, Chung Y-J, et al. Co-introduction of plasmids harbouring the carbapenemase genes, blaNDM-1 and blaOXA-23, increases fitness and virulence of bacterial host. J Biomed Sci. 2020;27:8.

48. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-Lactamases: the quiet before the storm? 2005;18:306–25.

49. Viana GF, Zago MCB, Moreira RRB, et al. Intraspecies Transfer of the Chromosomal Acinetobacter baumannii blaNDM-1 Carbapenemase Gene. Antimicrob Agents Chemother. 2016;60:3032–40.

50. Fouad M, Attaia AS, Tawakkol WM, Hashem AM. Emergence of carbapenem-resistant Acinetobacter baumannii harboring the OXA-23 carbapenemase in intensive care units of Egyptian hospitals. Int J Infect Dis. 2013;17:e1252–4.

51. Al-Agamy MH, Khalaf NG, Tawfick MM, Shibil AM, El Kholy A. Molecular characterization of carbapenem-insensitive Acinetobacter baumannii in Egypt. Int J Infect Dis. 2014;22:49–54.

52. El-Masry EA, El-Masry HA. Characterization of carbapenem-resistant Acinetobacter baumannii isolated from intensive care unit, Egypt. Egyp J Med Microbiol. 2018;27:85–91.

53. Al-Hassan L, El Mehalla H, Amyes SG. Diversity in Acinetobacter baumannii isolates from paediatric cancer patients in Egypt. Clin Microbiol Infect. 2013;19:1082–8.

54. Touati M, Diene SM, Racherache A, Dekhil M, Djahoudi A, Rollain JM. Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria. Int J Antimic Agents. 2012;40:89–91.

55. Tomaschek F, Higgins PG, Stefaniak D, Wisplinghoff H, Seifert H. Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of Acinetobacter baumannii outbreak and sporadic isolates. PloS ONE. 2016;11:e0153014-e.

56. Ghaith DM, Zafer MM, Al-Agamy MH, Alyamani EJ, Boooq RY, Almoazzamy O. The emergence of a novel sequence type of MDR Acinetobacter baumannii from the intensive care unit of an Egyptian tertiary care hospital. Ann Clin Microbiol Antimicrob. 2017;16:34.

57. Alyamani EJ, Khiyami MA, Boooq RY, Alnafjan BM, Altmamami MA, Bahwerth FS. Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann Clin Microbiol Antimicrob. 2015;14:38.

58. Chang Y, Luan G, Xu Y, et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol. 2015;6:910.

59. Al-Hassan LL, Al-Madboly LA. Molecular characterisation of an Acinetobacter baumannii outbreak. Infect Prevent Pract. 2020;2:100040.

60. Hua X, Zhou Z, Yang Q, et al. Evolution of Acinetobacter baumannii in vivo: international clone II, more resistance to ceftazidime, mutation in ptk. Front Microbiol. 2017;8:1256.

61. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70:119–23.